Literature DB >> 11139304

The changing face of chemotherapy in colorectal cancer.

J Waters1, D Cunningham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11139304      PMCID： PMC2363611          DOI： 10.1054/bjoc.2000.1552

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  13 in total

1.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

Authors:  A de Gramont; J Vignoud; C Tournigand; C Louvet; T André; C Varette; E Raymond; S Moreau; N Le Bail; M Krulik
Journal:  Eur J Cancer       Date:  1997-02       Impact factor: 9.162

2.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

4.  A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.

Authors:  P Ross; A Norman; D Cunningham; A Webb; T Iveson; A Padhani; J Prendiville; M Watson; A Massey; R Popescu; J Oates
Journal:  Ann Oncol       Date:  1997-10       Impact factor: 32.976

5.  Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.

Authors:  D Cunningham; J R Zalcberg; U Rath; I Oliver; E van Cutsem; C Svensson; J F Seitz; P Harper; D Kerr; G Perez-Manga
Journal:  Ann Oncol       Date:  1996-11       Impact factor: 32.976

6.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

7.  Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.

Authors:  R Pazdur; Y Lassere; V Rhodes; J A Ajani; S M Sugarman; Y Z Patt; D V Jones; A B Markowitz; J L Abbruzzese; B Bready
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

8.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

Authors:  D Cunningham; S Pyrhönen; R D James; C J Punt; T F Hickish; R Heikkila; T B Johannesen; H Starkhammar; C A Topham; L Awad; C Jacques; P Herait
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

9.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

Authors:  P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

10.  A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.

Authors:  D I Jodrell; A Bowman; R Rye; B Byrne; A Boddy; I Rafi; G A Taylor; A Johnston; N J Clendeninn
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640
View more
  6 in total

1.  Crypt dynamics and colorectal cancer: advances in mathematical modelling.

Authors:  I M M van Leeuwen; H M Byrne; O E Jensen; J R King
Journal:  Cell Prolif       Date:  2006-06       Impact factor: 6.831

2.  Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer.

Authors:  Hyuk-Chan Kwon; Kyoung Tae Kim; Shin Ae Lee; Jong-Sung Park; Sung-Hyun Kim; Jae-Seok Kim; Hyo Jin Kim
Journal:  Cancer Res Treat       Date:  2004-04-30       Impact factor: 4.679

3.  Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.

Authors:  Sung Yong Oh; Young-Tae Ju; Sang-Kyung Choi; Chang Yoon Ha; Won Sup Lee; Hoon Gu Kim; Gyeong-Won Lee; Hyuk-Chan Kwon; Jung Hun Kang
Journal:  Invest New Drugs       Date:  2010-03-19       Impact factor: 3.850

4.  HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.

Authors:  Weijun Liu; Zhenyong Zhang; Yongxue Zhang; Xinju Chen; Shikui Guo; Yi Lei; Yu Xu; Chao Ji; Zhigang Bi; Kunhua Wang
Journal:  Cancer Biol Ther       Date:  2015-03-16       Impact factor: 4.742

5.  Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy.

Authors:  P Gouveris; A C Lazaris; T G Papathomas; A Nonni; V Kyriakou; J Delladetsima; E S Patsouris; N Tsavaris
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-29       Impact factor: 4.553

6.  The role of peroxisome proliferator-activated receptors in colorectal cancer.

Authors:  Joo-In Park; Jong-Young Kwak
Journal:  PPAR Res       Date:  2012-09-11       Impact factor: 4.964
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.